Study Purpose: This study checks how well and safely dupilumab works for adults with chronic pruritus of unknown origin (CPUO), which means having itchy skin for no known reason. Dupilumab is given as an under-the-skin injection.

Study Design: There are two parts, Study A and Study B. People in Study A receive treatment for 24 weeks, while Study B lasts 12 weeks. Before treatment starts, there is a 4-week period where participants use a non-sedative antihistamine (a medicine that helps with allergies) and a moisturizer. After treatment, there is a 12-week follow-up. Overall, Study A lasts up to 44 weeks and Study B up to 32 weeks.

• Eligibility: Participants must be aged 18-90, have severe itching (score ≥7), and have tried other treatments without success.
• Exclusions: People with certain conditions, like active infections, cancer, or past dupilumab use, cannot join.
• Risk & Benefits: The study examines possible benefits of itch relief but also risks from the medication.

Note: Always talk to your doctor to understand if this study is right for you.